Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment
Open accessThe DOI matches its Crossref record; 269 of the 269 references it cites were found in a registry or an index.
Abstract
Ovarian cancer encompasses a heterogeneous group of malignancies that involve the ovaries, fallopian tubes and the peritoneal cavity. Despite major advances made within the field of cancer, the majority of patients with ovarian cancer are still being diagnosed at an advanced stage of the disease due to lack of effective screening tools. The overall survival of these patients has, therefore, not substantially improved over the past decades. Most patients undergo debulking surgery and treatment with chemotherapy, but often micrometastases remain and acquire resistance to the therapy, eventually leading to disease recurrence. Here, we summarize the current knowledge in epithelial ovarian cancer development and metastatic progression. For the most common subtypes, we focus further on the properties and functions of the immunosuppressive tumor microenvironment, including the extracellular matrix. Current and future treatment modalities are discussed and finally we provide an overview of the different experimental models used to develop novel therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
Levental, K. R., Yu, H., Kass, L., Lakins, J. N., Egeblad, M., Erler, J. T., Fong, S. F. T., Csiszar, K., Giaccia, A., Weninger, W., et al. (2009) · Cell · doi:10.1016/j.cell.2009.10.027 · Cited by 4,101
A framework for advancing our understanding of cancer-associated fibroblasts
Sahai, E., Astsaturov, I., Cukierman, E., DeNardo, D. G., Egeblad, M., Evans, R. M., Fearon, D., Greten, F. R., Hingorani, S. R., Hunter, T., et al. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0238-1 · Cited by 3,863
Ovarian cancer statistics, 2018
Torre, L. A., Trabert, B., DeSantis, C. E., Miller, K. D., Samimi, G., Runowicz, C. D., Gaudet, M. M., Jemal, A., & Siegel, R. L. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21456 · Cited by 3,492
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Sato, E., Olson, S. H., Ahn, J., Bundy, B., Nishikawa, H., Qian, F., Jungbluth, A. A., Frosina, D., Gnjatic, S., Ambrosone, C., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509182102 · Cited by 2,372
Concepts of extracellular matrix remodelling in tumour progression and metastasis
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J., & Werb, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-18794-x · Cited by 2,296
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
González-Martín, A., Pothuri, B., Vergote, I., DePont Christensen, R., Graybill, W., Mirza, M. R., McCormick, C., Lorusso, D., Hoskins, P., Freyer, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910962 · Cited by 2,263
Guidelines and definitions for research on epithelial-mesenchymal transition
Yang, J., Antin, P., Berx, G., Blanpain, C., Brabletz, T., Bronner, M., Campbell, K., Cano, A., Casanova, J., Christofori, G., et al. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-020-0237-9 · Cited by 2,226
A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian Cancer
Bast, R. C., Klug, T. L., John, E. S., Jenison, E., Niloff, J. M., Lazarus, H., Berkowitz, R. S., Leavitt, T., Griffiths, C. T., Parker, L., et al. (1983) · New England Journal of Medicine · doi:10.1056/nejm198310133091503 · Cited by 2,135
Orecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
Ray-Coquard, I., Pautier, P., Pignata, S., Pérol, D., González-Martín, A., Berger, R., Fujiwara, K., Vergote, I., Colombo, N., Mäenpää, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911361 · Cited by 2,055
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,048
Zheng, X., Carstens, J. L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V. S., & Kalluri, R. (2015) · Nature · doi:10.1038/nature16064 · Cited by 2,032
The extracellular matrix modulates the hallmarks of cancer
Pickup, M. W., Mouw, J. K., & Weaver, V. M. (2014) · EMBO reports · doi:10.15252/embr.201439246 · Cited by 1,996
Lheureux, S., Gourley, C., Vergote, I., & Oza, A. M. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32552-2 · Cited by 1,919
Self-citationThe tumor microenvironment at a glance
Balkwill, F. R., Capasso, M., & Hagemann, T. (2012) · Journal of Cell Science · doi:10.1242/jcs.116392 · Cited by 1,857
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
Fischer, K. R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S. T. C., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. (2015) · Nature · doi:10.1038/nature15748 · Cited by 1,791
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Up on the tightrope: natural killer cell activation and inhibition
Lanier, L. L. (2008) · Nature Immunology · doi:10.1038/ni1581 · Cited by 1,656
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Every step of the way: integrins in cancer progression and metastasis
Hamidi, H., & Ivaska, J. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0038-z · Cited by 1,493
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Staging classification for cancer of the ovary, fallopian tube, and peritoneum
Prat, J. (2014) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2013.10.001 · Cited by 1,364
Naba, A., Clauser, K. R., Hoersch, S., Liu, H., Carr, S. A., & Hynes, R. O. (2012) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.014647 · Cited by 1,354
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
Targeting the tumour stroma to improve cancer therapy
Valkenburg, K. C., de Groot, A. E., & Pienta, K. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0007-1 · Cited by 1,084
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Inherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
High grade serous ovarian carcinomas originate in the fallopian tube
Labidi-Galy, S. I., Papp, E., Hallberg, D., Niknafs, N., Adleff, V., Noe, M., Bhattacharya, R., Novak, M., Jones, S., Phallen, J., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00962-1 · Cited by 759
Menon, U., Gentry-Maharaj, A., Burnell, M., Singh, N., Ryan, A., Karpinskyj, C., Carlino, G., Taylor, J., Massingham, S. K., Raikou, M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00731-5 · Cited by 730
Extracellular matrix (ECM) stiffness and degradation as cancer drivers
Najafi, M., Farhood, B., & Mortezaee, K. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27681 · Cited by 715
Zou, W., Machelon, V., Coulomb-L'Hermin, A., Borvak, J., Nome, F., Isaeva, T., Wei, S., Krzysiek, R., Durand-Gasselin, I., Gordon, A., et al. (2001) · Nature Medicine · doi:10.1038/nm1201-1339 · Cited by 653
Molecular Cloning of the CA125 Ovarian Cancer Antigen
Yin, B. W. T., & Lloyd, K. O. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103554200 · Cited by 617
Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 576
Pujade-Lauraine, E., Wagner, U., Aavall-Lundqvist, E., Gebski, V., Heywood, M., Vasey, P. A., Volgger, B., Vergote, I., Pignata, S., Ferrero, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7519 · Cited by 575
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research
Kipps, E., Tan, D. S. P., & Kaye, S. B. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3432 · Cited by 562
Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage
Peres, L. C., Cushing-Haugen, K. L., Köbel, M., Harris, H. R., Berchuck, A., Rossing, M. A., Schildkraut, J. M., & Doherty, J. A. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy071 · Cited by 554
Ovarian Cancer Metastasis: Integrating insights from disparate model organisms
Naora, H., & Montell, D. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1611 · Cited by 538
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers
Cheng, K. W., Lahad, J. P., Kuo, W.-L., Lapuk, A., Yamada, K., Auersperg, N., Liu, J., Smith-McCune, K., Lu, K. H., Fishman, D., et al. (2004) · Nature Medicine · doi:10.1038/nm1125 · Cited by 509
A single-cell landscape of high-grade serous ovarian cancer
Izar, B., Tirosh, I., Stover, E. H., Wakiro, I., Cuoco, M. S., Alter, I., Rodman, C., Leeson, R., Su, M.-J., Shah, P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0926-0 · Cited by 504
Mechanisms of PARP inhibitor sensitivity and resistance
D’Andrea, A. D. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.021 · Cited by 489
Basic Immunology: Functions and Disorders of the Immune System
Dorak, M. T. (2002) · American Journal of Epidemiology · doi:10.1093/aje/155.2.185-a · Cited by 486
Miller, R. E., Leary, A., Scott, C. L., Serra, V., Lord, C. J., Bowtell, D., Chang, D. K., Garsed, D. W., Jonkers, J., Ledermann, J. A., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.08.2102 · Cited by 483
Fu, T., Dai, L.-J., Wu, S.-Y., Xiao, Y., Ma, D., Jiang, Y.-Z., & Shao, Z.-M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01103-4 · Cited by 480
Neutrophils facilitate ovarian cancer premetastatic niche formation in the omentum
Lee, W., Ko, S. Y., Mohamed, M. S., Kenny, H. A., Lengyel, E., & Naora, H. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181170 · Cited by 478
Tumor-Infiltrating Natural Killer Cells
Cózar, B., Greppi, M., Carpentier, S., Narni-Mancinelli, E., Chiossone, L., & Vivier, E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0655 · Cited by 476
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
Brentjens, R. J., Santos, E., Nikhamin, Y., Yeh, R., Matsushita, M., La Perle, K., Quintás-Cardama, A., Larson, S. M., & Sadelain, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0674 · Cited by 463
Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids
Hill, S. J., Decker, B., Roberts, E. A., Horowitz, N. S., Muto, M. G., Worley, M. J., Feltmate, C. M., Nucci, M. R., Swisher, E. M., Nguyen, H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0474 · Cited by 452
Dendritic cells in cancer: the role revisited
Veglia, F., & Gabrilovich, D. I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.002 · Cited by 443
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., Gentry-Maharaj, A., Hayward, J., Philpott, S., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv214 · Cited by 437
Webb, J. R., Milne, K., Watson, P., deLeeuw, R. J., & Nelson, B. H. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1877 · Cited by 434
γδ T cells: pleiotropic immune effectors with therapeutic potential in cancer
Silva-Santos, B., Mensurado, S., & Coffelt, S. B. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0153-5 · Cited by 425
Gubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
Poveda, A., Floquet, A., Ledermann, J. A., Asher, R., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Pignata, S., Friedlander, M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00073-5 · Cited by 422
Yin, M., Li, X., Tan, S., Zhou, H. J., Ji, W., Bellone, S., Xu, X., Zhang, H., Santin, A. D., Lou, G., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci87252 · Cited by 417
Pujade-Lauraine, E., Fujiwara, K., Ledermann, J. A., Oza, A. M., Kristeleit, R., Ray-Coquard, I.-L., Richardson, G. E., Sessa, C., Yonemori, K., Banerjee, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00216-3 · Cited by 416
Moore, K. N., Bookman, M., Sehouli, J., Miller, A., Anderson, C., Scambia, G., Myers, T., Taskiran, C., Robison, K., Mäenpää, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00306 · Cited by 414
Mutations in BRIP1 confer high risk of ovarian cancer
Rafnar, T., Gudbjartsson, D. F., Sulem, P., Jonasdottir, A., Sigurdsson, A., Jonasdottir, A., Besenbacher, S., Lundin, P., Stacey, S. N., Gudmundsson, J., et al. (2011) · Nature Genetics · doi:10.1038/ng.955 · Cited by 406
Oncogenic stress sensed by the immune system: role of natural killer cell receptors
Raulet, D. H., & Guerra, N. (2009) · Nature Reviews Immunology · doi:10.1038/nri2604 · Cited by 404
The Role of Tumor Microenvironment in Chemoresistance: To Survive, Keep Your Enemies Closer
Senthebane, D. A., Rowe, A., Thomford, N. E., Shipanga, H., Munro, D., Mazeedi, M. A. M. A., Almazyadi, H. A. M., Kallmeyer, K., Dandara, C., Pepper, M. S., et al. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071586 · Cited by 399
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Köbel, M., Kalloger, S. E., Huntsman, D. G., Santos, J. L., Swenerton, K. D., Seidman, J. D., & Gilks, C. B. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181c042b6 · Cited by 398
Huang, R.-Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 388
Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action
Abal, M., Andreu, J., & Barasoain, I. (2003) · Current Cancer Drug Targets · doi:10.2174/1568009033481967 · Cited by 383
Hornburg, M., Desbois, M., Lu, S., Guan, Y., Lo, A. A., Kaufman, S., Elrod, A., Lotstein, A., DesRochers, T. M., Munoz-Rodriguez, J. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.004 · Cited by 383
Hofheinz, R.-D., al-Batran, S.-E., Hartmann, F., Hartung, G., Jäger, D., Renner, C., Tanswell, P., Kunz, U., Amelsberg, A., Kuthan, H., et al. (2003) · Oncology Research and Treatment · doi:10.1159/000069863 · Cited by 374
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
Can advanced-stage ovarian cancer be cured?
Narod, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.224 · Cited by 369
Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
Zhang, A. W., McPherson, A., Milne, K., Kroeger, D. R., Hamilton, P. T., Miranda, A., Funnell, T., Little, N., de Souza, C. P. E., Laan, S., et al. (2018) · Cell · doi:10.1016/j.cell.2018.03.073 · Cited by 353
Pearce, O. M. T., Delaine-Smith, R. M., Maniati, E., Nichols, S., Wang, J., Böhm, S., Rajeeve, V., Ullah, D., Chakravarty, P., Jones, R. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0284 · Cited by 349
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
Harter, P., Sehouli, J., Vergote, I., Ferron, G., Reuss, A., Meier, W., Greggi, S., Mosgaard, B. J., Selle, F., Guyon, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103294 · Cited by 335
Schmalfeldt, B., Prechtel, D., Härting, K., Späthe, K., Rutke, S., Konik, E., Fridman, R., Berger, U., Schmitt, M., Kuhn, W. C., et al. (2001) · PubMed · Cited by 334
Ovarian cancer progression is controlled by phenotypic changes in dendritic cells
Scarlett, U. K., Rutkowski, M. R., Rauwerdink, A. M., Fields, J., Escovar-Fadul, X., Baird, J., Cubillos-Ruiz, J. R., Jacobs, A. C., Gonzalez, J. L., Weaver, J., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111413 · Cited by 315
Hematogenous Metastasis of Ovarian Cancer: Rethinking Mode of Spread
Pradeep, S., Kim, S. W., Wu, S. Y., Nishimura, M., Chaluvally-Raghavan, P., Miyake, T., Pecot, C. V., Kim, S.-J., Choi, H. J., Bischoff, F. Z., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.002 · Cited by 311
Marquez, R. T., Baggerly, K. A., Patterson, A. P., Liu, J., Broaddus, R., Frumovitz, M., Atkinson, E. N., Smith, D. I., Hartmann, L., Fishman, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2509 · Cited by 308
de Witte, C. J., Espejo Valle-Inclan, J., Hami, N., Lõhmussaar, K., Kopper, O., Vreuls, C. P. H., Jonges, G. N., van Diest, P., Nguyen, L., Clevers, H., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107762 · Cited by 303
Monk, B. J., Colombo, N., Oza, A. M., Fujiwara, K., Birrer, M. J., Randall, L., Poddubskaya, E. V., Scambia, G., Shparyk, Y. V., Lim, M. C., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00342-9 · Cited by 301
Tachibana, T., Onodera, H., Tsuruyama, T., Mori, A., Nagayama, S., Hiai, H., & Imamura, M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0877 · Cited by 295
Human exonuclease 1 and BLM helicase interact to resect DNA and initiate DNA repair
Nimonkar, A. V., Özsoy, A. Z., Genschel, J., Modrich, P., & Kowalczykowski, S. C. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809380105 · Cited by 295
Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells
Wang, J., & Wu, G. S. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.558288 · Cited by 291
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer
Worzfeld, T., Pogge von Strandmann, E., Huber, M., Adhikary, T., Wagner, U., Reinartz, S., & Müller, R. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00024 · Cited by 288
l -Arginine Depletion Blunts Antitumor T-cell Responses by Inducing Myeloid-Derived Suppressor Cells
Fletcher, M., Ramirez, M. E., Sierra, R. A., Raber, P., Thevenot, P., Al-Khami, A. A., Sanchez-Pino, D., Hernandez, C., Wyczechowska, D. D., Ochoa, A. C., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1491 · Cited by 281
The Emergence of Natural Killer Cells as a Major Target in Cancer Immunotherapy
Souza-Fonseca-Guimaraes, F., Cursons, J., & Huntington, N. D. (2019) · Trends in Immunology · doi:10.1016/j.it.2018.12.003 · Cited by 279
Zheng, X., Turkowski, K., Mora, J., Brüne, B., Seeger, W., Weigert, A., & Savai, R. (2017) · Oncotarget · doi:10.18632/oncotarget.17061 · Cited by 277
Mitra, A. K., Sawada, K., Tiwari, P., Mui, K., Gwin, K., & Lengyel, E. (2011) · Oncogene · doi:10.1038/onc.2010.532 · Cited by 274
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance
Gorodetska, I., Kozeretska, I., & Dubrovska, A. (2019) · Journal of Cancer · doi:10.7150/jca.30410 · Cited by 269
Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S., & Sehouli, J. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4035-8 · Cited by 261
The Impact of the Tumor Microenvironment on Macrophage Polarization in Cancer Metastatic Progression
Wang, H., Yung, M. M. H., Ngan, H. Y. S., Chan, K. K. L., & Chan, D. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126560 · Cited by 254
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Yuan, X., Zhang, J., Li, D., Mao, Y., Mo, F., Du, W., & Ma, X. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.07.007 · Cited by 250
Fibroblasts in the Tumor Microenvironment: Shield or Spear?
Alkasalias, T., Moyano-Galceran, L., Arsenian-Henriksson, M., & Lehti, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051532 · Cited by 247
Self-citationZhang, Y., Tang, H., Cai, J., Zhang, T., Guo, J., Feng, D., & Wang, Z. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.01.011 · Cited by 242
Zhang, S., Dolgalev, I., Zhang, T., Ran, H., Levine, D. A., & Neel, B. G. (2019) · Nature Communications · doi:10.1038/s41467-019-13116-2 · Cited by 240
Labidi-Galy, S. I., Sisirak, V., Meeus, P., Gobert, M., Treilleux, I., Bajard, A., Combes, J.-D., Faget, J., Mithieux, F., Cassignol, A., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0367 · Cited by 239
The Clinical Features of Ovarian Cancer in Hereditary Nonpolyposis Colorectal Cancer
Watson, P., Bützow, R., Lynch, H. T., Mecklin, J.-P., Järvinen, H. J., Vasen, H. F. A., Madlensky, L., Fidalgo, P., & Bernstein, I. (2001) · Gynecologic Oncology · doi:10.1006/gyno.2001.6279 · Cited by 236
Heterotypic CAF-tumor spheroids promote early peritoneal metastasis of ovarian cancer
Gao, Q., Yang, Z., Xu, S., Li, X., Yang, X., Jin, P., Liu, Y., Zhou, X., Zhang, T., Gong, C., et al. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20180765 · Cited by 236
Raghavan, S., Mehta, P., Xie, Y., Lei, Y. L., & Mehta, G. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0666-1 · Cited by 234
Gershenson, D. M., Miller, A., Brady, W. E., Paul, J., Carty, K., Rodgers, W., Millan, D., Coleman, R. L., Moore, K. N., Banerjee, S., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02175-9 · Cited by 232
Walker, J. L., Brady, M. F., Wenzel, L., Fleming, G. F., Huang, H. Q., DiSilvestro, P. A., Fujiwara, K., Alberts, D. S., Zheng, W., Tewari, K. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01568 · Cited by 231
The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach
Krijgsman, D., Hokland, M., & Kuppen, P. J. K. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00367 · Cited by 230
Giuntoli, R. L., Webb, T. J., Zoso, A., Rogers, O. C., Diaz-Montes, T. P., Bristow, R. E., & Oelke, M. (2009) · PubMed · Cited by 228
β1-Integrins Regulate the Formation and Adhesion of Ovarian Carcinoma Multicellular Spheroids
Casey, R. C., Burleson, K. M., Skubitz, K. M., Pambuccian, S. E., Oegema, T. R., Ruff, L. E., & Skubitz, A. P. N. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63058-1 · Cited by 225
Liu, J. F., Herold, C., Gray, K. P., Penson, R. T., Horowitz, N., Konstantinopoulos, P. A., Castro, C. M., Hill, S. J., Curtis, J., Luo, W., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.3343 · Cited by 222
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Coscia, F., Watters, K. M., Curtis, M., Eckert, M. A., Chiang, C. Y., Tyanova, S., Montag, A., Lastra, R. R., Lengyel, E., & Mann, M. (2016) · Nature Communications · doi:10.1038/ncomms12645 · Cited by 212
Replication Gaps Underlie BRCA Deficiency and Therapy Response
Panzarino, N. J., Krais, J. J., Cong, K., Peng, M., Mosqueda, M., Nayak, S. U., Bond, S. M., Calvo, J. A., Doshi, M. B., Bere, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1602 · Cited by 212
Malignant ascites: past, present, and future
Adam, R. A., & Adam, Y. G. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.01.035 · Cited by 209
Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours
Ince, T. A., Sousa, A. D., Jones, M. A., Harrell, J. C., Agoston, E. S., Krohn, M., Selfors, L. M., Liu, W., Chen, K., Yong, M., et al. (2015) · Nature Communications · doi:10.1038/ncomms8419 · Cited by 199
Zhang, K., Erkan, E. P., Jamalzadeh, S., Dai, J., Andersson, N., Kaipio, K., Lamminen, T., Mansuri, N., Huhtinen, K., Carpén, O., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm1831 · Cited by 197
Tumor microenvironment: The culprit for ovarian cancer metastasis?
Luo, Z., Wang, Q., Lau, W. B., Lau, B., Xu, L., Zhao, L., Yang, H., Feng, M., Xuan, Y., Yang, Y., et al. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.038 · Cited by 194
Tumor-Associated Macrophages Contribute to Tumor Progression in Ovarian Cancer
Colvin, E. K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00137 · Cited by 192
Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients
Lane, D., Matte, I., Rancourt, C., & Piché, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-210 · Cited by 190
Duraiswamy, J., Turrini, R., Minasyan, A., Barras, D., Crespo, I., Grimm, A. J., Casado, J., Genolet, R., Benedetti, F., Wicky, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.10.008 · Cited by 190
del Campo, J. M., Matulonis, U. A., Malander, S., Provencher, D., Mahner, S., Follana, P., Waters, J., Berek, J. S., Woie, K., Oza, A. M., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02238 · Cited by 189
Profiling of cytokines in human epithelial ovarian cancer ascites.
Matte, I., Lane, D. A., Laplante, C., Rancourt, C., & Piché, A. (2012) · Europe PMC (PubMed Central) · Cited by 188
Tumor evolution and chemoresistance in ovarian cancer
Kim, S., Han, Y., Kim, S. I., Kim, H.-S., Kim, S. J., & Song, Y. S. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0063-0 · Cited by 187
Davidson, B., Goldberg, I., Gotlieb, W. H., Kopolovic, J., Ben-Baruch, G., Nesland, J. M., Berner, A., Bryne, M., & Reich, R. (1999) · Clinical & Experimental Metastasis · doi:10.1023/a:1006723011835 · Cited by 183
Lecker, L. S. M., Berlato, C., Maniati, E., Delaine-Smith, R., Pearce, O. M. T., Heath, O. M., Nichols, S., Trevisan, C., Novak, M., McDermott, J. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0536 · Cited by 181
Bell-McGuinn, K. M., Matthews, C. M., Ho, S. N., Barve, M., Gilbert, L., Penson, R. T., Lengyel, E., Palaparthy, R., Gilder, K., Vassos, A., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.12.362 · Cited by 179
Krockenberger, M., Dombrowski, Y., Weidler, C., Ossadnik, M., Hönig, A., Häusler, S., Voigt, H., Becker, J. C., Leng, L., Steinle, A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7338 · Cited by 179
B7-H6-mediated downregulation of NKp30 in NK cells contributes to ovarian carcinoma immune escape
Pesce, S., Tabellini, G., Cantoni, C., Patrizi, O., Coltrini, D., Rampinelli, F., Matta, J., Vivier, E., Moretta, A., Parolini, S., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2014.1001224 · Cited by 178
Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer
Kim, S., Kim, B., & Song, Y. S. (2016) · Cancer Science · doi:10.1111/cas.12987 · Cited by 176
Co-evolution of Matrisome and Adaptive Adhesion Dynamics Drives Ovarian Cancer Chemoresistance
Pietilä, E. A., Gonzalez-Molina, J., Moyano-Galceran, L., Jamalzadeh, S., Zhang, K., Lehtinen, L., Turunen, S. P., Martins, T. A., Gultekin, O., Lamminen, T., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24009-8 · Cited by 175
Self-citationFunston, G., Hamilton, W. T., Abel, G., Crosbie, E. J., Rous, B., & Walter, F. M. (2020) · PLoS Medicine · doi:10.1371/journal.pmed.1003295 · Cited by 174
Cai, J., Tang, H., Xu, L., Wang, X., Yang, C., Ruan, S., Guo, J., Hu, S., & Wang, Z. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr230 · Cited by 173
The Clinical Relevance of Stromal Matrix Metalloproteinase Expression in Ovarian Cancer
Kamat, A. A., Fletcher, M., Gruman, L. M., Mueller, P., Lopez, A., Landen, C. N., Han, L., Gershenson, D. M., & Sood, A. K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2338 · Cited by 170
Takaishi, K., Komohara, Y., Tashiro, H., Ohtake, H., Nakagawa, T., Katabuchi, H., & Takeya, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01652.x · Cited by 170
Chemoresistance in human ovarian cancer: the role of apoptotic regulators
Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-1-66 · Cited by 170
Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives
Pujade-Lauraine, E., Banerjee, S., & Pignata, S. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00194 · Cited by 169
Precursors and pathogenesis of ovarian carcinoma
Lim, D. Y., & Oliva, E. (2013) · Pathology · doi:10.1097/pat.0b013e32835f2264 · Cited by 166
Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways
Chang, M.-C., Chen, C.-A., Chen, P.-J., Chiang, Y.-C., Chen, Y.-L., Mao, T.-L., Lin, H.-W., Lin Chiang, W.-H., & Cheng, W.-F. (2012) · Biochemical Journal · doi:10.1042/bj20110282 · Cited by 165
Al Habyan, S., Kalos, C., Szymborski, J., & McCaffrey, L. (2018) · Oncogene · doi:10.1038/s41388-018-0317-x · Cited by 162
Adipocytes Sequester and Metabolize the Chemotherapeutic Daunorubicin
Sheng, X., Parmentier, J., Tucci, J., Pei, H., Cortez-Toledo, O., Dieli-Conwright, C. M., Oberley, M. J., Neely, M. N., Orgel, E., Louie, S. G., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0338 · Cited by 156
Chambers, S. K., Kacinski, B. M., Ivins, C. M., & Carcangiu, M. L. (1997) · PubMed · Cited by 155
Membrane-type matrix metalloproteases as diverse effectors of cancer progression
Turunen, S. P., Tatti-Bugaeva, O., & Lehti, K. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.002 · Cited by 154
Self-citationMullamitha, S. A., Ton, N. C., Parker, G. J. M., Jackson, A., Julyan, P. J., Roberts, C., Buonaccorsi, G. A., Watson, Y., Davies, K., Cheung, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2779 · Cited by 146
Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N., & Takebayashi, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10608 · Cited by 146
Milky spots as the implantation site for malignant cells in peritoneal dissemination in mice.
Hagiwara, A., Takahashi, T., Sawai, K., Taniguchi, H., Shimotsuma, M., Okano, S., Sakakura, C., Tsujimoto, H., Osaki, K., & Sasaki, S. (1993) · PubMed · Cited by 145
Holzer, A. K., Katano, K., Klomp, L. W. J., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0748 · Cited by 143
Callahan, M. J., Nagymányoki, Z., Bonome, T., Johnson, M. E., Litkouhi, B., Sullivan, E. H., Hirsch, M. S., Matulonis, U. A., Liu, J. F., Birrer, M. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0479 · Cited by 143
Samimi, G., Varki, N. M., Wilczynski, S. P., Safaei, R., Alberts, D. S., & Howell, S. B. (2003) · PubMed · Cited by 139
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136
Immunotherapy in Ovarian Cancer: Are We There Yet?
Kandalaft, L. E., Odunsi, K. O., & Coukos, G. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00508 · Cited by 135
Pedersen, M., Westergaard, M. C. W., Milne, K., Nielsen, M., Borch, T. H., Poulsen, L. G., Hendel, H. W., Kennedy, M., Briggs, G., Ledoux, S., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1502905 · Cited by 135
Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass: Clues to Serous Tumor Origin?
Roh, M. H., Kindelberger, D. W., & Crum, C. P. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181868904 · Cited by 133
Collagen Remodeling in the Hypoxic Tumor-Mesothelial Niche Promotes Ovarian Cancer Metastasis
Natarajan, S., Foreman, K. M., Soriano, M. I., Rossen, N. S., Shehade, H., Fregoso, D. R., Eggold, J. T., Krishnan, V., Dorigo, O., Krieg, A. J., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2616 · Cited by 129
Genetic Analysis of the Early Natural History of Epithelial Ovarian Carcinoma
Pothuri, B., Leitão, M. M., Levine, D. A., Viale, A. J., Olshen, A. B., Arroyo, C. D., Bogomolniy, F., Olvera, N., Lin, O., Soslow, R. A., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010358 · Cited by 128
Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells
Cai, Q., Yan, L., & Xu, Y. (2015) · Oncogene · doi:10.1038/onc.2014.264 · Cited by 127
Targeting homologous recombination repair defects in cancer
Evers, B., Helleday, T., & Jonkers, J. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.06.001 · Cited by 127
Sawers, L., Ferguson, M. J., Ihrig, B. R., Young, H. C., Chakravarty, P., Wolf, C. R., & Smith, G. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.386 · Cited by 126
Raghavan, S. A., Mehta, P., Ward, M. R., Bregenzer, M. E., Fleck, E. M. A., Tan, L., McLean, K., Buckanovich, R. J., & Mehta, G. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0133 · Cited by 126
Aptsiauri, N., Ruiz‐Cabello, F., & Garrido, F. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.006 · Cited by 125
Mesothelin-Specific CAR T Cells Target Ovarian Cancer
Schoutrop, E., Serafi, I. E., Poiret, T., Zhao, Y. H., Gultekin, O., He, R., Moyano‐Galceran, L., Carlson, J. W., Lehti, K., Hassan, M., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2701 · Cited by 125
Self-citationEndosomes: Emerging Platforms for Integrin-Mediated FAK Signalling
Alanko, J., & Ivaska, J. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.02.001 · Cited by 120
Krishnan, V., Tallapragada, S., Schaar, B. T., Kamat, K., Chanana, A. M., Zhang, Y., Patel, S. A., Parkash, V., Rinker-Schaeffer, C. W., Folkins, A. K., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01246-z · Cited by 119
Tumiati, M., Hietanen, S., Hynninen, J., Pietilä, E. A., Färkkilä, A., Kaipio, K., Roering, P., Huhtinen, K., Alkodsi, A., Li, Y., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3770 · Cited by 117
Self-citationManiati, E., Berlato, C., Gopinathan, G., Heath, O. M., Kotantaki, P., Lakhani, A., McDermott, J. R., Pegrum, C., Delaine‐Smith, R. M., Pearce, O. M. T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.12.034 · Cited by 116
Bankert, R. B., Balu-Iyer, S. V., Odunsi, K., Shultz, L. D., Kelleher, R. J., Barnas, J. L., Simpson-Abelson, M., Parsons, R., & Yokota, S. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024420 · Cited by 115
Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors
Weidemann, S. A., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A. M., Kluth, M., Hube‐Magg, C., Blessin, N. C., Fraune, C., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9040397 · Cited by 115
Wu, L., Deng, Z., Peng, Y., Han, L., Liu, J., Wang, L., Li, B., Zhao, J., Jiao, S., & Wei, H. (2017) · Oncotarget · doi:10.18632/oncotarget.20164 · Cited by 114
Rynne‐Vidal, A., Au‐Yeung, C. L., Jiménez‐Heffernan, J. A., Pérez‐Lozano, M. L., Cremades‐Jimeno, L., Bárcena, C., Cristóbal‐García, I., Fernández‐Chacón, C., Yeung, T. L., Mok, S. C., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4889 · Cited by 112
Presence and role of stem cells in ovarian cancer
Šuster, N. K., & Virant‐Klun, I. (2019) · World Journal of Stem Cells · doi:10.4252/wjsc.v11.i7.383 · Cited by 111
Laumont, C. M., Wouters, M. C. A., Smazynski, J., Gierc, N. S., Chavez, E. A., Chong, L. C., Thornton, S., Milne, K., Webb, J. R., Steidl, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4394 · Cited by 110
Geisler, J. P., Goodheart, M. J., Sood, A. K., Holmes, R. J., Hatterman‐Zogg, M. A., & Buller, R. E. (2003) · Cancer · doi:10.1002/cncr.11770 · Cited by 110
Hussain, A., Voisin, V., Poon, S., Karamboulas, C., Bui, N. H. B., Meens, J., Dmytryshyn, J., Ho, V. W., Tang, K. H., Paterson, J., et al. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191094 · Cited by 108
Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells
Tesone, A. J., Rutkowski, M. R., Brencicova, E., Svoronos, N., Perales‐Puchalt, A., Stephen, T. L., Allegrezza, M. J., Payne, K. K., Nguyen, J. M., Wickramasinghe, J. M., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.056 · Cited by 108
Moss, N. M., Barbolina, M. V., Liu, Y., Sun, L., Munshi, H. G., & Stack, M. S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4151 · Cited by 105
Landskron, J., Helland, Ø., Torgersen, K. M., Aandahl, E. M., Gjertsen, B. T., Bjørge, L., & Taskén, K. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1636-6 · Cited by 105
Cancer Implications for Patients with Endometriosis
Wilbur, M. B., Shih, I., Segars, J. H., & Fader, A. N. (2017) · Seminars in Reproductive Medicine · doi:10.1055/s-0036-1597120 · Cited by 104
Okła, K., Czerwonka, A., Wawruszak, A., Bobiński, M. S., Bilska, M., Tarkowski, R., Bednarek, W., Wertel, I., & Kotarski, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00691 · Cited by 101
Diffuse Mesothelin Expression Correlates with Prolonged Patient Survival in Ovarian Serous Carcinoma
Yen, M. J., Hsu, C.-Y., Mao, T., Wu, T. ‐., Roden, R. B. S., Wang, T., & Shih, I. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1397 · Cited by 101
Dadgar, N., Gonzalez-Suarez, A. M., Fattahi, P., Hou, X., Weroha, J. S., Gaspar-Maia, A., Stybayeva, G., & Revzin, A. (2020) · Microsystems & Nanoengineering · doi:10.1038/s41378-020-00201-6 · Cited by 99
He, X., Ota, T., Liu, P., Su, C., CHIEN, J. R., & Shridhar, V. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3557 · Cited by 98
Drilling for Oil: Tumor-Surrounding Adipocytes Fueling Cancer
Attané, C., & Muller, C. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.03.001 · Cited by 97
Current Status of Patient-Derived Ovarian Cancer Models
Maru, Y., & Hippo, Y. (2019) · Cells · doi:10.3390/cells8050505 · Cited by 95
Single‐cell transcriptomes reveal heterogeneity of high‐grade serous ovarian carcinoma
Hao, Q., Li, J., Zhang, Q., Xu, F., Xie, B., Lu, H., Wu, X., & Zhou, X. Y. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.500 · Cited by 90
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer
Nersesian, S., Glazebrook, H. M., Toulany, J., Grantham, S. R., & Boudreau, J. E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01782 · Cited by 90
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer
Baert, T., Vankerckhoven, A., Riva, M., Hoylandt, A. V., Thirion, G., Gerhardt, H., Mathivet, T., Vergote, I. B., & Coosemans, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01273 · Cited by 89
First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
Marchetti, C., Muzii, L., Romito, A., & Panici, P. B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s155425 · Cited by 87
Bamias, A., Tsiatas, M. L., Kafantari, E., Liakou, C. G., Rodolakis, A., Voulgaris, Z., Vlachos, G. D., Papageorgiou, T., Tsitsilonis, O., Bamia, C., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.02.029 · Cited by 86
Kampan, N. C., Madondo, M., McNally, O., Stephens, A. N., Quinn, M. A., & Plebanski, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01482 · Cited by 86
Gonzalez, V. D., Huang, Y.-W., Delgado‐González, A., Chen, S.-Y., Donoso, K., Sachs, K., Gentles, A. J., Allard, G. M., Kolahi, K. S., Howitt, B. E., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109632 · Cited by 85
Foord, E., Arruda, L. C. M., Gaballa, A., Klynning, C., & Uhlin, M. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb0192 · Cited by 85
Hapke, S., Kessler, H., Luber, B., Benge, A., Hutzler, P., Höfler, H., Schmitt, M., & Reuning, U. (2003) · Biological Chemistry · doi:10.1515/bc.2003.120 · Cited by 84
MHC/HLA Class I Loss in Cancer Cells
Garrido, F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-17864-2_2 · Cited by 83
Molecular Identification of GD3 as a Suppressor of the Innate Immune Response in Ovarian Cancer
Webb, T. J., Li, X., Giuntoli, R. L., López, P. H. H., Heuser-Loy, C., Schnaar, R. L., Tsuji, M., Kurts, C., Oelke, M., & Schneck, J. P. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2695 · Cited by 82
Intraperitoneal Chemotherapy in Ovarian Cancer Remains Experimental
Gore, M., du Bois, A., & Vergote, I. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.0376 · Cited by 82
Omental immune aggregates and tumor metastasis within the peritoneal cavity
Sorensen, E. W., Gerber, S. A., Sedlacek, A. L., Rybalko, V., Chan, W. M., & Lord, E. M. (2009) · Immunologic Research · doi:10.1007/s12026-009-8100-2 · Cited by 81
Collagen-rich omentum is a premetastatic niche for integrin α2-mediated peritoneal metastasis
Huang, Y., Liang, C.-Y., Ritz, D., Coelho, R., Septiadi, D., Estermann, M., Cumin, C., Rimmer, N., Schötzau, A., López, M. N., et al. (2020) · eLife · doi:10.7554/elife.59442 · Cited by 80
Ovarian cancer stem cells: What progress have we made?
Al-Alem, L., Pandya, U. M., Baker, A. T., Bellio, C., Zarrella, B., Clark, J., DiGloria, C. M., & Rueda, B. R. (2018) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2018.12.010 · Cited by 79
Metadata
- Authors
- Schoutrop, E., Moyano-Galceran, L., Lheureux, S., Mattsson, J., Lehti, K., Dahlstrand, H., & Magalhaes, I.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-11
- Volume
- 86
- Issue
- Pt 3
- Pages
- 207-223
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W4223430921
- Cited by
- 176
- References
- 269
- FWCI
- 24.08
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.